New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023.

IF 5.3 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

European Heart Journal - Cardiovascular Pharmacotherapy Pub Date : 2024-05-04 DOI:10.1093/ehjcvp/pvae013

Juan Tamargo, Stefan Agewall, Claudio Borghi, Claudio Ceconi, Elisabetta Cerbai, Gheorghe A Dan, Péter Ferdinandy, Erik Lerkevang Grove, Bianca Rocca, Emma Magavern, Patrick Sulzgruber, Anne Grete Semb, Samuel Sossalla, Alexander Niessner, Juan Carlos Kaski, Dobromir Dobrev

{"title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023.","authors":"Juan Tamargo, Stefan Agewall, Claudio Borghi, Claudio Ceconi, Elisabetta Cerbai, Gheorghe A Dan, Péter Ferdinandy, Erik Lerkevang Grove, Bianca Rocca, Emma Magavern, Patrick Sulzgruber, Anne Grete Semb, Samuel Sossalla, Alexander Niessner, Juan Carlos Kaski, Dobromir Dobrev","doi":"10.1093/ehjcvp/pvae013","DOIUrl":null,"url":null,"abstract":"<p><p>Although cardiovascular diseases (CVDs) are the leading cause of death worldwide, their pharmacotherapy remains suboptimal. Thus, there is a clear unmet need to develop more effective and safer pharmacological strategies. In this review, we summarize the most relevant advances in cardiovascular pharmacology in 2023, including the approval of first-in-class drugs that open new avenues for the treatment of atherosclerotic CVD and heart failure (HF). The new indications of drugs already marketed (repurposing) for the treatment of obstructive hypertrophic cardiomyopathy, hypercholesterolaemia, type 2 diabetes, obesity, and HF; the impact of polypharmacy on guideline-directed drug use is highlighted as well as results from negative clinical trials. Finally, we end with a summary of the most important phase 2 and 3 clinical trials assessing the efficacy and safety of cardiovascular drugs under development for the prevention and treatment of CVDs.</p>","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":5.3000,"publicationDate":"2024-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11121198/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal - Cardiovascular Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ehjcvp/pvae013","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Although cardiovascular diseases (CVDs) are the leading cause of death worldwide, their pharmacotherapy remains suboptimal. Thus, there is a clear unmet need to develop more effective and safer pharmacological strategies. In this review, we summarize the most relevant advances in cardiovascular pharmacology in 2023, including the approval of first-in-class drugs that open new avenues for the treatment of atherosclerotic CVD and heart failure (HF). The new indications of drugs already marketed (repurposing) for the treatment of obstructive hypertrophic cardiomyopathy, hypercholesterolaemia, type 2 diabetes, obesity, and HF; the impact of polypharmacy on guideline-directed drug use is highlighted as well as results from negative clinical trials. Finally, we end with a summary of the most important phase 2 and 3 clinical trials assessing the efficacy and safety of cardiovascular drugs under development for the prevention and treatment of CVDs.

查看原文本刊更多论文

2023 年的新药剂和新型心血管药物治疗策略。

尽管心血管疾病是导致全球死亡的主要原因，但其药物治疗效果仍不理想。因此，开发更有效、更安全的药理策略显然是一项尚未满足的需求。在这篇综述中，我们总结了 2023 年心血管药理学领域最相关的进展，包括首创药物的批准，这些药物为动脉粥样硬化性心血管疾病和心力衰竭的治疗开辟了新途径。重点介绍了已上市药物用于治疗阻塞性肥厚型心肌病、高胆固醇血症、2 型糖尿病、肥胖症和心力衰竭的新适应症（再利用）、多药疗法对指南指导用药的影响以及阴性临床试验的结果。最后，我们总结了最重要的 2 期和 3 期临床试验，这些试验评估了正在开发的用于预防和治疗心血管疾病的心血管药物的疗效和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Heart Journal - Cardiovascular Pharmacotherapy Medicine-Cardiology and Cardiovascular Medicine

CiteScore

10.10

自引率

14.10%

发文量

期刊介绍： The European Heart Journal - Cardiovascular Pharmacotherapy (EHJ-CVP) is an international, peer-reviewed journal published in English, specifically dedicated to clinical cardiovascular pharmacology. EHJ-CVP publishes original articles focusing on clinical research involving both new and established drugs and methods, along with meta-analyses and topical reviews. The journal's primary aim is to enhance the pharmacological treatment of patients with cardiovascular disease by interpreting and integrating new scientific developments in this field. While the emphasis is on clinical topics, EHJ-CVP also considers basic research articles from fields such as physiology and molecular biology that contribute to the understanding of cardiovascular drug therapy. These may include articles related to new drug development and evaluation, the physiological and pharmacological basis of drug action, metabolism, drug interactions, and side effects.